Lv4
760 积分 2023-09-09 加入
Dapagliflozin and Empagliflozin in Paediatric Indications: A Systematic Review
3小时前
待确认
Pharmacokinetics of Empagliflozin and Pioglitazone After Coadministration in Healthy Volunteers
2天前
已完结
Pharmacokinetics, safety and tolerability of empagliflozin, a sodium glucose cotransporter 2 inhibitor, in patients with hepatic impairment
2天前
已完结
Pharmacokinetics, pharmacodynamics and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in subjects with renal impairment
2天前
已完结
Mechanistic Modeling of Empagliflozin: Predicting Pharmacokinetics, Urinary Glucose Excretion, and Investigating Compensatory Role of SGLT1 in Renal Glucose Reabsorption
9天前
已完结
Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction
23天前
已完结
The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial
23天前
已完结
A Model-Informed Approach to Accelerate the Clinical Development of Janagliflozin, an Innovative SGLT2 Inhibitor
24天前
已完结
Translational prediction of first-in-human pharmacokinetics and pharmacodynamics of janagliflozin, a selective SGLT2 inhibitor, using allometric scaling, dedrick and PK/PD modeling methods
24天前
已完结
Pharmacokinetics, pharmacodynamics and tolerability of single and multiple doses of janagliflozin, a sodium‐glucose co‐transporter‐2 inhibitor, in Chinese people with type 2 diabetes mellitus
24天前
已完结
皖公网安备34019202002308
